Business Context and Reporting Period
Company: Integer Holdings Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: June 8, 2018
Context: The Company entered into Amendment No. 4 to its Credit Agreement and issued notice of a conditional full redemption of its outstanding Senior Notes. These actions are directly tied to the previously announced sale of the Company's Advanced Surgical and Orthopedic ("AS&O") product lines.
Key Financial Metrics and Obligations
- Debt Instrument: 9.125% Senior Notes due 2023.
- Outstanding Principal: $360.0 million (as of June 8, 2018).
- Redemption Price: 100% of principal plus applicable premium and accrued interest.
- Planned Use of Proceeds (AS&O Sale):
- Redeem all outstanding 9.125% Senior Notes.
- Repay outstanding revolving credit loans (without reducing the credit commitment).
- Prepay outstanding Term B loans (if proceeds remain).
Material Changes and Agreements
The Company executed Amendment No. 4 to its Credit Agreement dated October 27, 2015. Key changes include:
- Authorization for the sale of the AS&O product lines.
- Mandated application of net cash proceeds from the sale to retire specific debt obligations.
- Modification of the "Adjusted EBITDA" definition to allow adjustments for non-recurring expenses related to the AS&O sale.
Outlook, Contingencies, and Risks
Contingency: The redemption of the $360.0 million Senior Notes is strictly conditioned on the closing of the AS&O sale.
Timeline: The scheduled redemption date is July 10, 2018, subject to extension pending the closing of the AS&O sale.
Management Commentary: The filing indicates a strategic shift to reduce leverage and restructure debt obligations using proceeds from the divestiture of the AS&O lines.
Investor Verification Checklist
- Confirm the closing status and final net cash proceeds of the AS&O product line sale.
- Verify the exact redemption price calculation, including the applicable premium and accrued interest for the Senior Notes.
- Monitor the July 10, 2018 redemption date for potential extensions if the AS&O sale is delayed.
- Review the impact of the "Adjusted EBITDA" definition change on future covenant compliance.